Futami, Shinji
Arai, Toru
Hirose, Masaki
Sugimoto, Chikatoshi
Ikegami, Naoya
Akira, Masanori
Kasai, Takahiko
Kitaichi, Masanori
Hayashi, Seiji
Inoue, Yoshikazu http://orcid.org/0000-0003-3994-874X
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (Respiratory Failure 17933141, Pulmonary alveolar proteinosis 17930161, H26-Nanchitoo (Nan)-ippann-076)
Intractable Respiratory Diseases and Pulmonary Hypertension Research Group of the Ministry of Health, Labour and Welfare (17933141)
the Japan Agency for Medical Research and Development (JP18ek0109268)
the National Hospital Organization Respiratory Diseases Network (H26-NHO (Kokyu)-01)
Article History
Received: 28 August 2018
Accepted: 9 October 2018
First Online: 20 October 2018
Ethics approval and consent to participate
: We obtained written informed consent from all participants prior to prospective assignment to the cohort, data collection, and serum collection (approval number: 365). The present study was also approved by the Institutional Review Board of the Kinki-Chuo Chest Medical Centre, Sakai City, Osaka, Japan (KCCMC; approval number: 531).
: All study participants provided written, informed consent.
: Y.I. is a member of the NobelPharma Co. advisory board. There are no other competing interest to report.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.